These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12478006)

  • 1. Lymphocyte subpopulations and interleukin levels in high-risk melanoma patients treated with high-dose interferon A-2B.
    Gogas H; Paterakis G; Frangia K; Bafaloukos D; Pectasides D; Kalofonos HP; Loukopoulos D; Stavropoulou-Giokas C; Ioannovich J; Mihm MC
    Am J Clin Oncol; 2002 Dec; 25(6):591-6. PubMed ID: 12478006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory T cells and other lymphocyte subpopulations in patients with melanoma developing interferon-induced thyroiditis during high-dose interferon-α2b treatment.
    Soldevila B; Alonso N; Martínez-Arconada MJ; Granada ML; Boada A; Vallejos V; Fraile M; Fernández-Sanmartín MA; Pujol-Borrell R; Puig-Domingo M; Sanmartí A; Martínez-Cáceres EM
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):621-8. PubMed ID: 22957689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
    Ascierto PA; Napolitano M; Celentano E; Simeone E; Gentilcore G; Daponte A; Capone M; Caracò C; Calemma R; Beneduce G; Cerrone M; De Rosa V; Palmieri G; Castello G; Kirkwood JM; Marincola FM; Mozzillo N
    J Transl Med; 2010 Aug; 8():76. PubMed ID: 20712892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma.
    Dréau D; Foster M; Hogg M; Swiggett J; Holder WD; White RL
    Oncol Res; 2000; 12(5):241-51. PubMed ID: 11417749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.
    Millar BC; Bell JB; Powles RL
    Br J Cancer; 1996 Jan; 73(2):236-40. PubMed ID: 8546912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.
    Santin AD; Bellone S; Palmieri M; Bossini B; Dunn D; Roman JJ; Pecorelli S; Cannon M; Parham GP
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1345-55. PubMed ID: 12459356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.
    Konjević G; Jović V; Jurisić V; Radulović S; Jelić S; Spuzić I
    Clin Exp Metastasis; 2003; 20(7):647-55. PubMed ID: 14669796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of immune changes in patients with renal cancer and melanoma treated with interferon-alpha 2b.
    Tsavaris N; Baxevanis K; Kosmidis P; Papamichael M
    Tumour Biol; 1995; 16(6):365-73. PubMed ID: 7569683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of interferon-alpha-2b on the clinical course, inflammatory skin infiltrates and peripheral blood lymphocytes in patients with severe atopic eczema.
    Gruschwitz MS; Peters KP; Heese A; Stosiek N; Koch HU; Hornstein OP
    Int Arch Allergy Immunol; 1993; 101(1):20-30. PubMed ID: 8499770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
    Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
    Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
    Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
    Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
    Lesinski GB; Kondadasula SV; Crespin T; Shen L; Kendra K; Walker M; Carson WE
    J Natl Cancer Inst; 2004 Sep; 96(17):1331-42. PubMed ID: 15339971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of gonadotropin treatment on the immunological features of male patients with idiopathic hypogonadotropic hypogonadism.
    Yesilova Z; Ozata M; Kocar IH; Turan M; Pekel A; Sengul A; Ozdemír IC
    J Clin Endocrinol Metab; 2000 Jan; 85(1):66-70. PubMed ID: 10634365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgE, CD8(+)CD60+ T cells and IFN-alpha in human immunity to parvovirus B19 in selective IgA deficiency.
    Bluth MH; Norowitz KB; Chice S; Shah VN; Nowakowski M; Durkin HG; Smith-Norowitz TA
    Hum Immunol; 2005 Oct; 66(10):1029-38. PubMed ID: 16386644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
    Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
    Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of peripheral blood T-cell subsets, natural killer cells and serum levels of cytokines in children with Down syndrome.
    Cetiner S; Demirhan O; Inal TC; Tastemir D; Sertdemir Y
    Int J Immunogenet; 2010 Aug; 37(4):233-7. PubMed ID: 20477881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-gamma+ and interleukin-2+ T cells in peripheral blood from multiple myeloma patients in relation to disease status and maintenance therapy with interferon-alpha2b (intron A).
    Millar BC; Millar JL; Powles RL; Catovsky D
    Br J Haematol; 1997 Jul; 98(1):119-25. PubMed ID: 9233574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased frequency of intracellular interleukin (IL)-13 and IL-10, but not IL-4, expressing CD4+ and CD8+ peripheral T cells of patients with atopic dermatitis.
    Aleksza M; Lukács A; Antal-Szalmás P; Hunyadi J; Szegedi A
    Br J Dermatol; 2002 Dec; 147(6):1135-41. PubMed ID: 12452862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia.
    Panoskaltsis N; Reid CD; Knight SC
    Leukemia; 2003 Apr; 17(4):716-30. PubMed ID: 12682629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.